A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia-Reference-Cited by-同舟云学术

A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia

Published:2017-10 Issue: Volume:61 Page:89-95
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Verstovsek Srdan,Mesa Ruben A.,Salama Mohamed E.,Li Li,Pitou Celine,Nunes Fabio P.,Price Gregory L.,Giles Jennifer L.,D’Souza Deborah N.,Walgren Richard A.,Prchal Josef T.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference34 articles.

1. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms;Tefferi;Leukemia,2008

2. The evolving treatment paradigm in myelofibrosis;Mesa;Leuk. Lymphoma,2013

3. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients;Mesa;Cancer,2007

4. Myelofibrosis with myeloid metaplasia;Tefferi;N. Engl. J. Med.,2000

5. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera;Journal of Clinical Medicine;2024-08-22

2. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis;Annals of Hematology;2024-03-18

3. Signaling networks guiding erythropoiesis;Current Opinion in Hematology;2024-02-07

4. Exploring the untapped pharmacological potential of imidazopyridazines;RSC Advances;2024

5. Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis;Expert Opinion on Investigational Drugs;2023-10-03